Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Albany Molecular Research, Inc. and Lead Plaintiff Deadline of January 12, 2015

News provided by

Jan 09, 2015, 10:00 ET

NEW YORK, Jan. 9, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the Eastern District of New York on behalf of those who purchased shares of Albany Molecular Research, Inc. ("Albany Molecular" or the "Company") (NasdaqGS: AMRI) shares during the period between August 5, 2014 and November 5, 2014 (the "Class Period").

The Complaint alleges that throughout the Class Period defendants issued materially false and misleading statements about the Company's operations, financial performance and prospects, including statements issued by Albany Molecular concerning the Company's financial guidance and operations at its OsoBio facility.

On November 5, 2014, Albany Molecular announced weak financial and operating results for third quarter 2014, including an $8.6 million loss in the quarter. The Company attributed these results to a "confluence of a business interruption event at our OsoBio facility, together with lower Discovery and API revenue." In addition, the Company disclosed a "weather-related power interruption at our OsoBio facility in Albuquerque took the facility offline for a period of time, contributing to the loss of finished product and the need to remediate one of the suites at the facility." Following this news, Albany Molecular stock declined nearly 27%, or $6.08 per share, to close at $16.59 per share on November 5, 2014.

Plaintiff seeks to recover damages on behalf of all shareholders who purchased shares of Albany Molecular during the Class Period described above.

No Class has yet been certified in the above action. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Albany Molecular you have until January 12, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
[email protected]

SOURCE Bronstein, Gewirtz & Grossman, LLC